Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling

Identifying molecular residual disease (MRD) after treatment of localized lung cancer could facilitate early intervention and personalization of adjuvant therapies. Here, we apply cancer personalized profi ling by deep sequencing (CAPP-seq) circulating tumor DNA (ctDNA) analysis to 255 samples from...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Discov
Autors principals: Chaudhuri, Aadel A., Chabon, Jacob J., Lovejoy, Alexander F., Newman, Aaron M., Stehr, Henning, Azad, Tej D., Khodadoust, Michael S., Esfahani, Mohammad Shahrokh, Liu, Chih Long, Zhou, Li, Scherer, Florian, Kurtz, David M., Say, Carmen, Carter, Justin N., Merriott, David J., Dudley, Jonathan C., Binkley, Michael S., Modlin, Leslie, Padda, Sukhmani K., Gensheimer, Michael F., West, Robert B., Shrager, Joseph B., Neal, Joel W., Wakelee, Heather A., Loo, Billy W., Alizadeh, Ash A., Diehn, Maximilian
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5895851/
https://ncbi.nlm.nih.gov/pubmed/28899864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-17-0716
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars